Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


03.10.2017

2 AJR Am J Roentgenol
4 BJU Int
1 BMC Cancer
1 Cancer Lett
1 Clin Cancer Res
1 Eur J Radiol
5 Eur Urol
1 Int J Radiat Oncol Biol Phys
1 J Natl Cancer Inst
1 J Nucl Med
8 J Urol
2 N Engl J Med
1 PLoS Genet
4 PLoS One
1 Prog Urol
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. WOO S, Suh CH, Kim SY, Cho JY, et al
    Head-To-Head Comparison Between High- and Standard-b-Value DWI for Detecting Prostate Cancer: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2017 Sep 27:1-10. doi: 10.2214/AJR.17.18480.
    PubMed     Text format     Abstract available

  2. GLAZER DI, Mayo-Smith WW, Sainani NI, Sadow CA, et al
    Interreader Agreement of Prostate Imaging Reporting and Data System Version 2 Using an In-Bore MRI-Guided Prostate Biopsy Cohort: A Single Institution's Initial Experience.
    AJR Am J Roentgenol. 2017 Jun 28:W1-W7. doi: 10.2214/AJR.16.17551.
    PubMed     Text format     Abstract available


    BJU Int

  3. VAN STAM MA, van der Poel HG, van der Voort van Zyp JRN, Tillier CN, et al
    The accuracy of patients' perceptions of the risks associated with localized prostate cancer treatments.
    BJU Int. 2017 Sep 28. doi: 10.1111/bju.14034.
    PubMed     Text format     Abstract available

  4. BLANCHARD P, Davis JW, Frank SJ, Kim J, et al
    Quality of life following brachytherapy or bilateral nerve sparing robotic prostatectomy for prostate cancer: a prospective cohort.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14021.
    PubMed     Text format     Abstract available

  5. RULACH R, McKay S, Neilson S, White L, et al
    Real World Uptake, Safety Profile and Outcomes of Docetaxel in Newly Diagnosed Metastatic Prostate Cancer.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14025.
    PubMed     Text format     Abstract available

  6. BOSCO C, Wong C, Garmo H, Crawley D, et al
    Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14023.
    PubMed     Text format     Abstract available


    BMC Cancer

  7. ABHYANKAR N, Hoskins KF, Abern MR, Calip GS, et al
    Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
    BMC Cancer. 2017;17:659.
    PubMed     Text format     Abstract available


    Cancer Lett

  8. EL-SAYED IY, Daher A, Destouches D, Firlej V, et al
    Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.
    Cancer Lett. 2017 Sep 19. pii: S0304-3835(17)30560.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  9. KALINA JL, Neilson DS, Lin YY, Hamilton PT, et al
    Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.0618.2017.
    PubMed     Text format     Abstract available


    Eur J Radiol

  10. BECKER AS, Cornelius A, Reiner CS, Stocker D, et al
    Direct comparison of PI-RADS version 2 and version 1 regarding interreader agreement and diagnostic accuracy for the detection of clinically significant prostate cancer.
    Eur J Radiol. 2017;94:58-63.
    PubMed     Text format     Abstract available


    Eur Urol

  11. FARIA R, Soares MO, Spackman E, Ahmed HU, et al
    Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    Eur Urol. 2017 Sep 18. pii: S0302-2838(17)30711.
    PubMed     Text format     Abstract available

  12. MILLER K, Carles J, Gschwend JE, Van Poppel H, et al
    The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Eur Urol. 2017 Sep 19. pii: S0302-2838(17)30728.
    PubMed     Text format     Abstract available

  13. PANSADORO V, Brassetti A
    Re: Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30782.
    PubMed     Text format    

  14. GASSER T
    Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-term Oncologic Outcomes in a Shared Equal-access Health System.
    Eur Urol. 2017 Sep 20. pii: S0302-2838(17)30727.
    PubMed     Text format    

  15. CAPOGROSSO P, Montorsi F
    Erectile Function Recovery After Surgery in Young Men with Low-risk Prostate Cancer: Probably Not Just a Matter of Age, Certainly Not the Main Point of Discussion.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30726.
    PubMed     Text format    


    Int J Radiat Oncol Biol Phys

  16. REIS FERREIRA M, Khan A, Thomas K, Truelove L, et al
    Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Aug 2. pii: S0360-3016(17)33655.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  17. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    J Nucl Med

  18. FENDLER WP, Cutler C
    More alpha than beta for prostate cancer?
    J Nucl Med. 2017 Sep 21. pii: jnumed.117.198333. doi: 10.2967/jnumed.117.198333.
    PubMed     Text format    


    J Urol

  19. GARCIA-REYES K, Nguyen HG, Zagoria RJ, Shinohara K, et al
    Impact of lesion visibility on transrectal ultrasound on the prediction of clinically significant prostate cancer (Gleason score >/= 3+4) with TRUS-MRI fusion biopsy.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77560-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  20. NYAME YA, Grimberg DC, Greene DJ, Gupta K, et al
    Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77563-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  21. SHIOTA M, Fujimoto N, Takeuchi A, Kashiwagi E, et al
    The association of polymorphisms in the gene encoding gonadotropin releasing hormone with serum testosterone level during androgen-deprivation therapy and prognosis in metastatic prostate cancer.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77562-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  22. NGUYEN HG, Welty C, Lindquist K, Ngo V, et al
    Validation of GEMCaP as a DNA based biomarker to predict prostate cancer recurrence after radical prostatectomy.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77554-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  23. SANDA MG
    Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Pro.
    J Urol. 2017 Sep 22. pii: S0022-5347(17)77389-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format    

  24. TOSOIAN JJ, Carter HB
    Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con.
    J Urol. 2017 Sep 22. pii: S0022-5347(17)77388-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format    

  25. HEILBRUN LK, Powell IJ
    Re: Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy: M. S. Leapman, S. J. Freedland, W. J. Aronson, C. J. Kane, M. K. T
    J Urol. 2017 Sep 26. pii: S0022-5347(17)77419-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format    

  26. XU X, Zhang X, Zhong Y, Saad F, et al
    Dynamic Patterns of Testosterone Levels within Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77561-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    N Engl J Med


  27. Prostatectomy versus Observation for Early Prostate Cancer.
    N Engl J Med. 2017;377:1301-1303.
    PubMed     Text format    

  28. SHARMA V, Karnes RJ
    Prostatectomy versus Observation for Early Prostate Cancer.
    N Engl J Med. 2017;377:1302.
    PubMed     Text format    


    PLoS Genet

  29. CAMACHO N, Van Loo P, Edwards S, Kay JD, et al
    Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.
    PLoS Genet. 2017;13:e1007001.
    PubMed     Text format     Abstract available


    PLoS One

  30. REULEN RC, de Vogel S, Zhong W, Zhong Z, et al
    Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer.
    PLoS One. 2017;12:e0178613.
    PubMed     Text format     Abstract available

  31. ROUVIERE O, Dagonneau T, Cros F, Bratan F, et al
    Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers.
    PLoS One. 2017;12:e0178901.
    PubMed     Text format     Abstract available

  32. ZHAO A, Chen F, Ning C, Wu H, et al
    Use of real-time cellular analysis and Plackett-Burman design to develop the serum-free media for PC-3 prostate cancer cells.
    PLoS One. 2017;12:e0185470.
    PubMed     Text format     Abstract available

  33. YU EJ, Hooker E, Johnson DT, Kwak MK, et al
    LZTS2 and PTEN collaboratively regulate ss-catenin in prostatic tumorigenesis.
    PLoS One. 2017;12:e0174357.
    PubMed     Text format     Abstract available


    Prog Urol

  34. RENARD-PENNA R, Sanchez-Salas R, Barret E, Cosset JM, et al
    [Evaluation and results of ablative therapies in prostate cancer].
    Prog Urol. 2017 Sep 19. pii: S1166-7087(17)30455.
    PubMed     Text format     Abstract available


    Urology

  35. QURESHI ZP, Sartor O, Bennett CL
    Calling Order to Chaos: Treatment Decision Making in Metastatic Castrate-resistant Prostate Cancer.
    Urology. 2017 Sep 20. pii: S0090-4295(17)30750.
    PubMed     Text format    

  36. SHORE N, Heidenreich A, Saad F
    Author Response on the Manuscript Titled "Calling Order to Chaos: Treatment Decision Making in Metastatic Castrate-resistant Prostate Cancer" (#URL-D-17-01121).
    Urology. 2017 Sep 20. pii: S0090-4295(17)30751.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: